Kyowa Kirin Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Kyowa Kirin Co., Ltd.
The confluence of data science and molecular biology fuels expectations among biopharma industry leaders for another year of breakthrough innovation in human therapeutics. More than 70 executives and experts reveal what they are most excited about on the technology front.
McKesson’s exit from the space forced sponsors to switch vendors managing their REMS programs, which in some instances affected patient access to drugs. Omnibus legislation requires GAO report and collection of public input on factors FDA should consider in reviewing vendor changes.
As the usual flurry of deals coincides with the J.P. Morgan Healthcare Conference, AbbVie signed an mRNA pact with Anima and a cancer research tie-up with Immunome.
Amgen has signed two big early-stage deals in a matter of days, signalling that antibody-drug conjugates are a priority target in oncology for the firm.
- In Vitro Diagnostics
- Research, Analytical Equipment & Supplies
- Radiopharmaceuticals, Contrast Agents
- Drug Discovery Tools
- Other Names / Subsidiaries
- Archimedes Pharma Ltd.
- Centus Biotherapeutics Ltd.
- Daiichi Fine Chemical Co., Ltd.
- Fujifilm Kyowa Kirin Biologics Co., Ltd.
- Kirin Pharma Company, Limited
- Kyowa Kirin Asia Pacific Pte. Ltd.
- Kyowa Kirin Australia Pty Ltd
- Kyowa Kirin International PLC
- Kyowa Pharma Chemical Co., Ltd.
- ProStrakan Group plc
- Kyowa Kirin
- Kyowa Kirin Frontier Co., Ltd.
- Kyowa Hakko Kirin (Singapore) Pte. Ltd.
- Kyowa Hakko Kirin Co., Ltd.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.